Journal
CELL DEATH & DISEASE
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-018-0309-3
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81773782, 81473248, 81621064]
- CAMS Major Collaborative Innovation Project [2016-12M-1-011]
- Central and Non-profitable Basic R&D Funds for Scientific Research Institutes [2016ZX350043]
Ask authors/readers for more resources
Glycogen synthase kinase-3 beta (GSK-3 beta) is a ubiquitously expressed serine/threonine kinase involved in a variety of functions ranging from the control of glycogen metabolism to transcriptional regulation. We recently demonstrated that GSK-3 beta inhibition triggered ASK1-JNK-dependent apoptosis in human hepatocellular carcinoma (HCC) cells. However, the comprehensive picture of downstream GSK-3 beta-regulated pathways/functions remains elusive. In this study, we showed that GSK-3 beta was aberrantly activated in HCC. Pharmacological inhibition and genetic depletion of GSK-3 beta suppressed the growth and induced caspase-dependent apoptosis in HCC cells. In addition, GSK-3 beta inhibition-induced apoptosis through downregulation of c-FLIPL in HCC, which was caused by biogenesis of functional lysosomes and subsequently c-FLIPL translocated to lysosome for degradation. This induction of the lysosome-dependent c-FLIPL degradation was associated with nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis. Moreover, GSK-3 beta inhibition-induced TFEB translocation acts through activation of AMPK and subsequently suppression of mTOR activity. Thus our findings reveal a novel mechanism by which inhibition of GSK-3 beta promotes lysosome-dependent degradation of c-FLIPL. Our study shows that GSK-3 beta may become a promising therapeutic target for HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available